clinical trial · NCT07150988
A Phase II Efficacy and Safety Study of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis
Haisco Pharmaceutical Group Co., Ltd.·phase2·not yet recruiting·n = 150
PsoriasisHSK44459 dose level 1HSK44459 dose level 2placebo
brief summary
The purpose of this study is to assess the efficacy and safety of HSK44459 administered orally for moderate to severe plaque psoriasis in adults.
started
Sep 26, 2025
primary completion
Nov 6, 2026
completion
Nov 6, 2026
last updated
Sep 2, 2025
detailed description
Patients with moderate to severe plaque psoriasis will be randomized into 3 cohorts (dose level 1, dose level 2 and placebo). Approximately 150 subjects will be enrolled. This study includes an 16-week treatment Period, then a 4-week safety visit period.
official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol